Bioequivalence trials share
RecordSTO-HEBDQ5W4X2-1WJNF05KTY-PFNKZQ
China · 2025
Bioequivalence trials share in China was 42.5% in 2025 (NHSA).
Clinical trial registrations in China: every year, the rank and how it is measured
- Publisher
- NHSA
- Authority tier
- T1 Official
- Locator
- 试验包括新药临床试验和生物等效性试验
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
其中，新药临床试验2997项，占比57.5%，同比增长18%；生物等效性试验2218项，占比42.5%。
Checked: the figure 42.5%is stated in this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
APA
National Healthcare Security Administration. (2025). 从“0”到“1”创新能力增强 我国新药研发热度持续攀升. Retrieved September 17, 2026, from http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Via StatOrigin, https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ
Other formats: MLA, Chicago, BibTeX
- MLA
- National Healthcare Security Administration. "从“0”到“1”创新能力增强 我国新药研发热度持续攀升." 2025, http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ.
- Chicago
- National Healthcare Security Administration. "从“0”到“1”创新能力增强 我国新药研发热度持续攀升." 2025. http://www.nhsa.gov.cn/art/2026/6/23/art_14_21076.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ.
- BibTeX
- @misc{nhsa2025bioequivalencepfnkzq, author = {{National Healthcare Security Administration}}, title = {从“0”到“1”创新能力增强 我国新药研发热度持续攀升}, year = {2025}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ}, note = {Original source: http://www.nhsa.gov.cn/art/2026/6/23/art\_14\_21076.html. Accessed September 17, 2026.} }
Data published under CC BY 4.0. The citation credits the original publisher and links to this permanent record.
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary source
- Publisher
- National Healthcare Security Administration · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- 从“0”到“1”创新能力增强 我国新药研发热度持续攀升
- Type
- Press release
- Published
- —
- Locator
- 试验包括新药临床试验和生物等效性试验
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification
- Status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 17 September 2026
- Permanent URL
- /stat/stat_HEBDQ5W4X21WJNF05KTYPFNKZQ